From GlobeNewswire.
– Tesla’s stock price fell 3.5% after announcing a delay in the production of its electric semi-truck.
– Apple reported a 20% increase in iPhone sales, driving its stock price up by 5%.
– The S&P 500 index reached a new record high, closing at 4,500 points.
– Amazon announced plans to invest $1 billion in opening new fulfillment centers across the US.: 2025-03-27 02:30:00

CROSSJECT reports financial results for 2024, including a cash position of 7 million euros as of December 31. The company continues to make progress in the development of ZEPIZURE®, an emergency solution for epileptic seizures, with a focus on FDA approval through BARDA funding. Tony Tipton joins as Chief Operating Officer USA.

The contract with BARDA for ZEPIZURE® is valued at $92 million, potentially rising to $155 million. Progress includes research and development costs of 8.2 million euros in 2024, compared to 6.2 million euros in 2023. FDA approval for ZEPIZURE® under the Emergency Use Authorization procedure is a key milestone for CROSSJECT.

CROSSJECT’s industrial production in 2024 and 2025 has been successful, with validation batches underway. A New Drug Application (NDA) for ZEPIZURE® in the US is expected by mid-2026. The ZENEO® platform, used for injections, is set to continue demonstrating precision and low variability for market acceptance.

The company’s R&D programs, ZENEO® Hydrocortisone and ZENEO® Adrenaline, are advancing towards registration in the US or Europe from H2 2026. Additionally, a collaboration with Eton Pharmaceuticals, Inc for ZENEO® Hydrocortisone aims to capture a significant share of the adrenal insufficiency market in the US. FDA filings are anticipated from H2 2026. CROSSJECT strengthened its balance sheet in 2024 with financing from Heights Capital Management (HCM) and Gemmes Venture, raising a total of 12 million euros. Additional funding included a capital increase of 8 million euros and government awards totaling 8.6 million euros. Operating income remained stable at 13.3 million euros, with operating expenses increasing by 4% compared to 2023. Personnel expenses amounted to 7.8 million euros, and the company had 106 employees in France and 2 in the US. Operating loss for 2024 was 13.0 million euros, with a net financial result of -1.4 million euros. In 2024, CROSSJECT saw a net profit of -12.8 million euros, a decrease from -8.6 million euros in 2023. The company’s cash position improved with approximately €7 million in cash at the end of 2024 compared to €2 million in 2023. Funding efforts continue with a focus on financing the business plan until commercial orders from BARDA begin.

In 2024, CROSSJECT received non-dilutive funding of 6.9 million euros from the French Government for projects under the France 2030 plan. Additional funding was secured through Heights Capital Management, with a total of 7 million euros raised in two tranches. A capital increase of approximately 8 million euros was also successful, with Gemmes Venture among the subscribers.

Production milestones for ZEPIZURE® were achieved in 2024 and 2025, including regulatory batch stability testing and successful audits of production sites. These milestones are crucial for FDA submissions and potential marketing authorizations. The company’s Gender Equality Index remained high at 93/100 in 2024, demonstrating commitment to gender equality in the workplace. In the first quarter of 2025, CROSSJECT announced progress in collaboration with Eton Pharmaceuticals, Inc. for the development of ZENEO® Hydrocortisone, a ready-to-use liquid formulation of hydrocortisone. Eton will market the product as ET-800 in the U.S. and expects to capture a significant share of the $100 million hospital market for injectable hydrocortisone products.

Eton Pharmaceuticals confirmed its commitment to ZENEO® Hydrocortisone as a disruptive solution for patients with adrenal insufficiency, with estimated market opportunity exceeding $100 million. The next stages of development and manufacturing are expected to begin in early 2026. CROSSJECT will collect a royalty of close to 10% on net sales by Eton of ET-800 and retain the right to market the product outside the United States and Canada.

CROSSJECT SA is an emerging specialty pharmaceuticals company developing medicines for emergency situations with its ZENEO® platform. The company is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, with a $60 million contract with BARDA. The ZENEO® platform enables patients or untrained caregivers to easily deliver emergency drugs via intramuscular injection on bare skin or through clothing. Other products in development include solutions for allergic shocks and adrenal insufficiencies.



Read more at GlobeNewswire.
– Tesla’s stock price fell 3.5% after announcing a delay in the production of its electric semi-truck.
– Apple reported a 20% increase in iPhone sales, driving its stock price up by 5%.
– The S&P 500 index reached a new record high, closing at 4,500 points.
– Amazon announced plans to invest $1 billion in opening new fulfillment centers across the US.:: CROSSJECT reports financial results for 2024